» Articles » PMID: 29794134

Molecular Basis for the Loss-of-function Effects of the Alzheimer's Disease-associated R47H Variant of the Immune Receptor TREM2

Abstract

Triggering receptor expressed on myeloid cells 2 (TREM2) is an immune receptor expressed on the surface of microglia, macrophages, dendritic cells, and osteoclasts. The R47H TREM2 variant is a significant risk factor for late-onset Alzheimer's disease (AD), and the molecular basis of R47H TREM2 loss of function is an emerging area of TREM2 biology. Here, we report three high-resolution structures of the extracellular ligand-binding domains (ECDs) of R47H TREM2, apo-WT, and phosphatidylserine (PS)-bound WT TREM2 at 1.8, 2.2, and 2.2 Å, respectively. The structures reveal that Arg plays a critical role in maintaining the structural features of the complementarity-determining region 2 (CDR2) loop and the putative positive ligand-interacting surface (PLIS), stabilizing conformations capable of ligand interaction. This is exemplified in the PS-bound structure, in which the CDR2 loop and PLIS drive critical interactions with PS via surfaces that are disrupted in the variant. Together with and characterization, our structural findings elucidate the molecular mechanism underlying loss of ligand binding, putative oligomerization, and functional activity of R47H TREM2. They also help unravel how decreased and stability of TREM2 contribute to loss of function in disease.

Citing Articles

Predicting the impact of missense mutations on an unresolved protein's stability, structure, and function: A case study of Alzheimer's disease-associated TREM2 R47H variant.

Pillai J, Sung K, Wu C Comput Struct Biotechnol J. 2025; 27:564-574.

PMID: 39989617 PMC: 11847478. DOI: 10.1016/j.csbj.2025.01.024.


Extracellular domain of TREM2 possess two distinct ligand recognition sites: Insights from machine-learning guided docking and all-atoms molecular dynamics simulations.

Mishra S, Swain P, Pati S, Dehury B Heliyon. 2025; 11(1):e41414.

PMID: 39866401 PMC: 11759634. DOI: 10.1016/j.heliyon.2024.e41414.


Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer's disease ligands.

Greven J, Wydra J, Greer R, Zhi C, Price D, Svoboda J Mol Neurodegener. 2025; 20(1):3.

PMID: 39789647 PMC: 11721465. DOI: 10.1186/s13024-024-00795-9.


Lipids: Emerging Players of Microglial Biology.

Prakash P, Randolph C, Walker K, Chopra G Glia. 2024; 73(3):657-677.

PMID: 39688320 PMC: 11784843. DOI: 10.1002/glia.24654.


Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model.

Carling G, Fan L, Foxe N, Norman K, Wong M, Zhu D Neuron. 2024; 112(23):3877-3896.e8.

PMID: 39353433 PMC: 11624100. DOI: 10.1016/j.neuron.2024.09.006.


References
1.
Bailey C, DeVaux L, Farzan M . The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J Biol Chem. 2015; 290(43):26033-42. PMC: 4646256. DOI: 10.1074/jbc.M115.677286. View

2.
Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X . The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J. 2017; 36(13):1837-1853. PMC: 5494459. DOI: 10.15252/embj.201796516. View

3.
Read C, Kuijper J, Hjorth S, Heipel M, Tang X, Fleetwood A . Cutting Edge: identification of neutrophil PGLYRP1 as a ligand for TREM-1. J Immunol. 2015; 194(4):1417-21. PMC: 4319313. DOI: 10.4049/jimmunol.1402303. View

4.
Chothia C, Janin J . Principles of protein-protein recognition. Nature. 1975; 256(5520):705-8. DOI: 10.1038/256705a0. View

5.
Yuan P, Condello C, Keene C, Wang Y, Bird T, Paul S . TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 2016; 90(4):724-39. PMC: 4898967. DOI: 10.1016/j.neuron.2016.05.003. View